Cargando…
Female sexual dysfunction: a focus on flibanserin
Flibanserin is the first US Food and Drug Administration (FDA)-approved option for sexual dysfunction, specifically low sexual desire. Until recently, there were no FDA-approved medication options to assist the ~40% of women affected by female sexual dysfunction (FSD). Often, patients report feeling...
Autor principal: | Lodise, Nicole M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644557/ https://www.ncbi.nlm.nih.gov/pubmed/29066935 http://dx.doi.org/10.2147/IJWH.S83747 |
Ejemplares similares
-
New developments in the treatment of hypoactive sexual desire disorder – a focus on Flibanserin
por: Jayne, Christopher J, et al.
Publicado: (2017) -
Flibanserin for Treating Hypoactive Sexual Desire Disorder
por: Sang, Jae Hong, et al.
Publicado: (2016) -
Flibanserin: A controversial drug for female hypoactive sexual desire disorder
por: Baid, Rashmi, et al.
Publicado: (2018) -
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder
por: Simon, James A., et al.
Publicado: (2022) -
Flibanserin Approval: Facts or Feelings?
por: Simon, James A., et al.
Publicado: (2016)